Preeclampsia Red Flags: What the Evidence Shows Every OB Should Know
An original evidence synthesis across 11 studies — covering severe-feature recognition, angiogenic biomarkers, aspirin prophylaxis gaps, atypical presentations, and postpartum vigilance. Evidence level: moderate to high (guidelines, systematic reviews, and large prospective studies). Through 2026.
This is an original evidence synthesis. See References for source studies.
One-Minute Takeaway
One-Minute Takeaway
- Preeclampsia red flags extend well beyond elevated blood pressure and proteinuria: the ACOG Practice Bulletin 222 and the 2021 ISSHP classification both emphasise that end-organ dysfunction — including thrombocytopenia, hepatic injury, renal insufficiency, cerebral symptoms, and pulmonary oedema — can define the diagnosis even without proteinuria.
- The sFlt-1/PlGF ratio has emerged as a powerful short-term prediction tool, with a ratio ≤38 providing a negative predictive value of 99.3% for ruling out preeclampsia within one week in the landmark PROGNOSIS study (Zeisler et al. 2016, NEJM).
- Low-dose aspirin (81 mg/day) initiated before 16 weeks of gestation may reduce preeclampsia risk by 15–40%, yet documented use remains below 50% among eligible patients, pointing to a critical implementation gap (USPSTF 2021, ACOG/SMFM 2021).
- Postpartum preeclampsia can present up to 6 weeks after delivery, and the long-term cardiovascular risk following any preeclamptic pregnancy is substantially elevated — yet systematic postpartum monitoring protocols remain inconsistently implemented.
Why Preeclampsia Red Flags Matter Now
Hypertensive disorders of pregnancy remain a leading cause of maternal mortality worldwide, and rates continue to climb. In the United States, the estimated prevalence of hypertensive disorders in pregnancy has nearly tripled over three decades — from approximately 2.8% in 1989 to 8.2% by 2020. Preeclampsia alone complicates 2–8% of pregnancies globally, contributing to over 50,000 maternal deaths and more than 500,000 fetal deaths each year.
What makes preeclampsia particularly dangerous is the discrepancy between the simplicity of its textbook definition and the complexity of its clinical presentation. The classical triad of hypertension, proteinuria, and oedema misses a substantial proportion of affected patients. Modern definitions now recognise that preeclampsia can present without proteinuria when other signs of end-organ damage are present — and that the disease does not end with delivery.
For obstetricians, the clinical challenge is twofold: identifying which patients will develop preeclampsia before it becomes severe, and recognising the atypical presentations that mimic other conditions. Both tasks require a thorough understanding of the evolving evidence base — from updated diagnostic criteria and angiogenic biomarkers to prevention strategies and postpartum risk monitoring.
What Evidence Was Reviewed
This synthesis integrates findings from major society guidelines (ACOG, ISSHP, SOGC, NICE), landmark biomarker trials, systematic reviews of aspirin prophylaxis, and recent meta-analyses on angiogenic factor performance. The evidence spans the full clinical trajectory — from first-trimester risk stratification to postpartum cardiovascular follow-up.
| Study | Design | n | Population | Key Finding | Quality |
|---|---|---|---|---|---|
| ACOG Practice Bulletin 222 (2020) | Clinical guideline | NR | Pregnant women (US) | Updated diagnostic criteria: proteinuria no longer mandatory; severe features defined | High |
| Magee et al. 2022 (ISSHP) | International classification/guideline | NR | Pregnant women globally | HDP classification based on timing, proteinuria, and organ dysfunction; angiogenic markers included | High |
| Zeisler et al. 2016 (PROGNOSIS, NEJM) | Prospective multicentre observational | 1,050 | Suspected preeclampsia (24–36 weeks) | sFlt-1/PlGF ratio ≤38: NPV 99.3% for ruling out preeclampsia within 1 week | High |
| Verlohren et al. 2022 (Consensus) | Expert consensus | NR | At-risk pregnancies | Practical guidance for sFlt-1/PlGF ratio integration into clinical management | Moderate |
| SR/MA on sFlt-1/PlGF (2025) | SR/MA | NR | Pregnant women with/without PE | sFlt-1/PlGF sensitivity 0.83, specificity 0.88, AUC 0.92 for PE prediction | Moderate |
| USPSTF 2021 (Aspirin SR) | SR (18 RCTs) | 15,908 | At-risk pregnant persons | Low-dose aspirin reduces preeclampsia, preterm birth, and perinatal mortality | High |
| ACOG/SMFM 2021 (Practice Advisory) | Clinical guidance update | NR | Pregnant persons (US) | Expanded moderate-risk criteria for aspirin prophylaxis; emphasised equity factors | High |
| SOGC Guideline 426 (2022) | Clinical guideline | NR | Pregnant women (Canada) | Adverse conditions framework for preeclampsia; transport/management protocols | High |
| O&G Open 2025 (Aspirin use study) | Repeated cross-sectional | 31,555 | Nulliparous patients (US) | Aspirin use remains below 50% despite updated guidelines; racial disparities in uptake | Moderate |
| Verlohren et al. 2020 (Hypertension) | Retrospective cohort | NR | Women with suspected PE | Multimarker model (sFlt-1/PlGF + clinical) AUC 88.7% for adverse outcomes vs. 69% for BP + proteinuria alone | Moderate |
| DSOG 2025 (Danish guideline) | Clinical guideline | NR | Pregnant women (Denmark) | Recommends against "mild" vs "severe" terminology; emphasises home BP monitoring and lifelong follow-up | Moderate |
Key Findings: Preeclampsia Red Flags and Evolving Recognition
Beyond Proteinuria: The Expanded Severe-Feature Framework
The modern diagnostic framework for preeclampsia has moved decisively away from proteinuria as a gatekeeper criterion. Both ACOG Practice Bulletin 222 and the ISSHP 2021 classification define preeclampsia as new-onset hypertension after 20 weeks accompanied by proteinuria OR end-organ dysfunction — including thrombocytopenia (platelets below 100,000/μL), hepatic dysfunction (transaminases elevated to twice the upper limit of normal), renal insufficiency (creatinine exceeding 1.1 mg/dL or doubling in the absence of other renal disease), pulmonary oedema, and new-onset cerebral or visual disturbances.
This shift reflects decades of evidence showing that a substantial proportion of women develop end-organ damage before proteinuria becomes detectable. The SOGC guideline takes this further by defining an "adverse conditions" framework that includes laboratory abnormalities, fetal compromise (growth restriction, abnormal Doppler indices), and maternal symptoms as collectively determining the severity trajectory. Notably, the 2025 Danish guideline recommends abandoning the terms "mild" and "severe" preeclampsia altogether, instead describing the disease by the specific organ systems affected and the rate of clinical progression.
Angiogenic Biomarkers: From Research to Bedside
The sFlt-1/PlGF ratio represents one of the most significant advances in preeclampsia risk stratification. The PROGNOSIS study — a prospective, multicentre trial of 1,050 women with suspected preeclampsia — established that a ratio at or below 38 effectively ruled out the development of preeclampsia within one week, with a negative predictive value of 99.3% (95% CI 97.9–99.9). When the ratio exceeded 38, the positive predictive value for preeclampsia within four weeks was 36.7% (95% CI 28.4–45.7), with sensitivity of 66.2% and specificity of 83.1%.
A 2025 systematic review and meta-analysis synthesising data across multiple populations confirmed the strong discriminative performance of this ratio, reporting a pooled sensitivity of 0.83 (95% CI 0.77–0.88), specificity of 0.88 (95% CI 0.82–0.92), and area under the curve of 0.92 for preeclampsia prediction — outperforming either marker measured alone. When combined with clinical parameters in a multimarker model, the area under the curve reached 88.7%, compared with 69.0% for blood pressure and proteinuria combined.
The clinical utility of these markers is most compelling in the "diagnostic uncertainty" zone — women presenting with non-specific symptoms such as headache, oedema, or borderline blood pressure elevations where traditional criteria are equivocal. In this population, a low sFlt-1/PlGF ratio can safely reduce unnecessary admissions and serial testing, while a high ratio identifies women needing closer surveillance. However, availability remains limited in many healthcare systems, and integration into standardised clinical protocols is still evolving.
The Aspirin Prophylaxis Gap: Evidence vs. Implementation
The evidence supporting low-dose aspirin for preeclampsia prevention is robust and consistent. The USPSTF systematic review, encompassing 18 RCTs with nearly 16,000 participants, confirmed reduced risks of preeclampsia, preterm birth, and perinatal mortality. Effect estimates suggest aspirin may reduce preeclampsia risk by 15–40%, with even greater reductions — up to 50% — for the most severe forms when initiated before 16 weeks of gestation.
Despite this strong evidence base, a 2025 analysis of over 31,000 nulliparous patients in a US health system found that documented aspirin use remained below 50% among eligible patients. Updated ACOG/SMFM guidance that emphasised lower income and Black race as moderate risk factors (the latter serving as a proxy for the health impacts of systemic racism) was associated with increased aspirin use among Black patients but did not significantly improve uptake among those with public insurance. This implementation gap represents one of the most actionable missed opportunities in contemporary obstetric care.
Preeclampsia can masquerade as multiple non-obstetric conditions, and delayed recognition is a well-documented contributor to adverse outcomes. Right upper quadrant or epigastric pain mimics biliary disease, pancreatitis, or peptic ulcer disease. New-onset headache with visual disturbances may be attributed to migraine or tension headache. Nausea and vomiting after 20 weeks can be dismissed as gastroenteritis. Acute dyspnoea from pulmonary oedema may suggest pneumonia or cardiac decompensation.
The threshold for suspecting preeclampsia should be low in any pregnant woman after 20 weeks presenting with symptoms in these domains. HELLP syndrome — characterised by haemolysis, elevated liver enzymes, and low platelet count — represents the most dangerous atypical variant and can present with minimal hypertension. Up to 15% of HELLP cases occur without meeting traditional hypertension thresholds, making laboratory assessment essential in any symptomatic pregnant patient in the second half of pregnancy.
The clinical red flags that should trigger immediate evaluation include: persistent severe headache unresponsive to standard analgesics, visual scotomata or blurred vision, right upper quadrant tenderness, rapid weight gain exceeding 1 kg per week, new-onset oedema of the face and hands (particularly when sudden), oliguria, and shortness of breath at rest. These symptoms warrant prompt blood pressure measurement, urinalysis, complete blood count with platelets, liver transaminases, creatinine, and consideration of angiogenic biomarker testing where available.
The clinical significance of timing in preeclampsia cannot be overstated. Early-onset disease (before 34 weeks) is strongly associated with defective placental trophoblastic invasion and subsequent uteroplacental hypoperfusion — the "placental" phenotype. It tends to be more severe, progress more rapidly, and is disproportionately associated with fetal growth restriction, abnormal uterine artery Doppler findings, and adverse maternal outcomes including HELLP syndrome and eclampsia.
Late-onset disease (at or after 34 weeks) is more common and is increasingly understood as a maternal phenotype driven by pre-existing cardiovascular susceptibility interacting with the physiological burden of pregnancy. Late-onset preeclampsia is more likely to present with borderline or fluctuating blood pressures, less dramatic laboratory derangement, and a lower frequency of fetal growth restriction. However, this lower perceived severity can breed complacency — late-onset disease can still progress to eclampsia, particularly if early warning signs are minimised.
The sFlt-1/PlGF ratio shows different patterns in each subtype: angiogenic imbalance tends to be more pronounced and develops earlier in early-onset preeclampsia, while late-onset disease may show a less dramatic but clinically significant rise closer to term. Understanding these distinctions helps clinicians calibrate their surveillance intensity and intervention thresholds according to the gestational age at presentation.
Preeclampsia does not invariably resolve with delivery. Postpartum preeclampsia — defined as new-onset hypertension with features of preeclampsia occurring after delivery — can manifest up to 6 weeks postpartum, though most cases present within the first week. Women who experienced preeclampsia during pregnancy are at highest risk, but de novo postpartum preeclampsia can occur in patients with entirely uncomplicated antenatal courses.
The 2025 Danish guideline explicitly recommends continuing antihypertensive treatment for at least one week after delivery and advocates lifelong annual blood pressure monitoring for all women with any hypertensive disorder of pregnancy. This reflects accumulating evidence that preeclampsia — particularly the early-onset, severe subtype — confers enduring cardiovascular risk. Multiple large cohort studies have shown that women with a history of preeclampsia face a 2- to 4-fold increase in lifetime cardiovascular disease, including hypertension, coronary heart disease, stroke, and heart failure.
The practical challenge is that the traditional postpartum visit at 4–6 weeks represents a single contact point that may miss the acute postpartum window entirely, while the long-term cardiovascular implications require engagement with primary care systems that may lack awareness of obstetric history as a cardiovascular risk factor. Structured postpartum blood pressure monitoring protocols — including home blood pressure measurement in the first 1–2 weeks — and explicit handoff of cardiovascular risk information to primary care are among the strategies being adopted at institutional level.
Identifying women at elevated risk for preeclampsia in the first trimester enables both aspirin prophylaxis and enhanced surveillance. ACOG/SMFM define high-risk factors as: prior preeclampsia (especially with adverse outcome), multifetal gestation, chronic hypertension, renal disease, autoimmune disease (particularly lupus or antiphospholipid syndrome), and pre-gestational type 1 or type 2 diabetes. Any single high-risk factor warrants aspirin prophylaxis.
Moderate-risk factors — where two or more in combination trigger aspirin consideration — include nulliparity, age ≥35 years, BMI >30, family history of preeclampsia, sociodemographic factors (including Black race as a proxy for the effects of systemic racism and lower income), and personal history factors such as previous adverse pregnancy outcome or a pregnancy interval exceeding 10 years.
The FIGO-recommended multivariate algorithm, which combines mean arterial pressure, uterine artery pulsatility index, serum PAPP-A, and PlGF at 11–13 weeks, achieves substantially better detection rates than clinical risk factor assessment alone — identifying roughly 75% of early-onset preeclampsia cases at a 10% false positive rate compared with approximately 40% for risk-factor screening. However, this combined approach requires ultrasound capabilities and biochemical assays that are not universally accessible, and its adoption varies considerably by region and practice setting.
Quality and Consistency of the Evidence
What the Evidence Does Not Yet Show
Biomarker-guided management has not been proven to improve hard outcomes. While the sFlt-1/PlGF ratio has excellent diagnostic and short-term predictive accuracy, no large randomised trial has demonstrated that clinical management guided by these biomarkers — as opposed to standard care — leads to reduced maternal or perinatal morbidity or mortality. The evidence currently supports better risk stratification but not yet measurably better outcomes.
Optimal aspirin dosing and timing are not fully resolved. The FIGO guideline recommends 150 mg nightly, while ACOG recommends 81 mg daily — the only low-dose formulation widely available in the US. Whether higher doses or evening administration offer meaningful additional benefit remains debated, with observational data suggesting potential advantages but no definitive head-to-head RCT evidence.
Population-specific sFlt-1/PlGF thresholds are not yet validated. The ratio of 38 was derived and validated primarily in European cohorts. Preliminary US data suggest that cut-off performance may vary by race, ethnicity, and BMI, and population-specific calibration studies are ongoing. Until these are complete, universal application of a single threshold carries some uncertainty.
No prospective evidence demonstrates that intensive postpartum cardiovascular follow-up reduces long-term cardiovascular events. While the elevated risk is well-documented, the assumption that identifying and treating modifiable risk factors early in the postpartum period translates to meaningful decades-long benefit remains unproven. Ongoing cohort studies and registry initiatives are expected to address this question over the next decade.
Practical Implications for Clinical Practice
Based on the current evidence, the following considerations may inform clinical approach to preeclampsia red flag recognition and response. These reflect what the evidence supports — not prescriptive directives — and should be adapted to local guidelines, resources, and individual patient context.
Waiting for proteinuria delays diagnosis in a meaningful proportion of patients. Systematic assessment of platelets, transaminases, creatinine, and symptoms should accompany any blood pressure concern after 20 weeks. A structured checklist approach may reduce missed diagnoses.
Where available, the sFlt-1/PlGF ratio is most useful in the clinical uncertainty zone — symptomatic patients not yet meeting full diagnostic criteria. A ratio ≤38 provides strong reassurance (NPV 99.3%) that preeclampsia is unlikely within one week, potentially enabling safe outpatient management.
Universal risk screening at the first prenatal visit with systematic aspirin initiation before 16 weeks for eligible patients is one of the most evidence-based interventions available. Institutional protocols or clinical decision support may help close the documented implementation gap.
Evidence supports structured blood pressure monitoring in the first 1–2 weeks postpartum and explicit documentation of hypertensive disorder history for long-term primary care handoff. Women with preeclampsia history should be informed of their elevated lifetime cardiovascular risk.
Evidence Grade and Bottom Line
Overall Evidence Grade: Moderate to Strong
The diagnostic framework for preeclampsia red flags is well-supported by high-quality guideline processes and consistent observational evidence. Aspirin prophylaxis is backed by high-quality RCT evidence. Angiogenic biomarkers have strong diagnostic accuracy data, though evidence that biomarker-guided management improves hard clinical outcomes is still maturing. Postpartum and long-term cardiovascular risk evidence is consistent and compelling, though optimal follow-up strategies remain evidence-poor.
- Preeclampsia diagnosis no longer requires proteinuria — end-organ dysfunction (thrombocytopenia, hepatic injury, renal insufficiency, cerebral symptoms, pulmonary oedema) is sufficient.
- The sFlt-1/PlGF ratio ≤38 rules out preeclampsia within one week with 99.3% negative predictive value, offering high-confidence triage in equivocal presentations.
- Low-dose aspirin before 16 weeks reduces preeclampsia risk by 15–40%, but use among eligible patients remains below 50% — systematic first-trimester risk screening is an actionable priority.
- Preeclampsia is a lifelong cardiovascular risk marker; structured postpartum monitoring and primary care handoff of obstetric history are essential for long-term prevention.
- Key limitation: biomarker-guided management has not yet been shown in RCTs to improve hard clinical outcomes versus standard care, and population-specific sFlt-1/PlGF thresholds await validation.
Article Information
For Educational Purposes Only. This is an original evidence synthesis informed by the studies listed below. It does not replace clinical judgement. Drug dosages should be verified against current prescribing information.
References
- Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222. Obstet Gynecol. 2020;135(6):e237–e260. DOI: 10.1097/AOG.0000000000003891
- Magee LA, Brown MA, Hall DR, et al. The 2021 International Society for the Study of Hypertension in Pregnancy classification, diagnosis & management recommendations for international practice. Pregnancy Hypertens. 2022;27:148–169. DOI: 10.1016/j.preghy.2021.09.008
- Zeisler H, Llurba E, Chantraine F, et al. Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. N Engl J Med. 2016;374(1):13–22. DOI: 10.1056/NEJMoa1414838
- Verlohren S, Brennecke SP, Galindo A, et al. Clinical interpretation and implementation of the sFlt-1/PlGF ratio in the prediction, diagnosis and management of preeclampsia. Pregnancy Hypertens. 2022;27:42–50. DOI: 10.1016/j.preghy.2021.12.003
- Wei Y, et al. Predictive performance of sFlt-1, PlGF and the sFlt-1/PlGF ratio for preeclampsia: A systematic review and meta-analysis. Pregnancy Hypertens. 2025. DOI: 10.1016/j.preghy.2025.101177
- Henderson JT, Vesco KK, Senger CA, Thomas RG, Redmond N. Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2021;326(12):1192–1206. DOI: 10.1001/jama.2021.8551
- ACOG/SMFM Practice Advisory. Low-Dose Aspirin Use for the Prevention of Preeclampsia and Related Morbidity and Mortality: Updated Recommendations. December 2021. Available from: acog.org
- Magee LA, et al. SOGC Clinical Practice Guideline No. 426: Hypertensive Disorders of Pregnancy: Diagnosis, Prediction, Prevention, and Management. J Obstet Gynaecol Can. 2022;44(5):547–571.e1. DOI: 10.1016/j.jogc.2022.03.002
- Changes in Low-Dose Aspirin Use After Updated Guidance on Preeclampsia Prevention. O&G Open. 2025;2(2):e069. DOI: 10.1097/og9.0000000000000069
- Verlohren S, et al. Prediction of Preeclampsia-Related Adverse Outcomes With the sFlt-1/PlGF-Ratio in the Clinical Routine. Hypertension. 2020;76(2):397–407. DOI: 10.1161/HYPERTENSIONAHA.120.15146
- DSOG Guideline Bulletin: Preeclampsia and Hypertension. Danish Journal of Obstetrics and Gynaecology. 2025;Issue 3:43–53. DOI: 10.56182/p4t63j54
- Magee LA. Preeclampsia. N Engl J Med. 2022;386(19):1817–1832. DOI: 10.1056/NEJMra2109523